Physician profile
Adrienne E Callahan
NPI 1639512551
$721.04
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $103 · 2023: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $99.99 · Food and Beverage: $32.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $99.99 |
| Food and Beverage | $32.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $153.65 | 2019-2020 | |
| Janssen Biotech, INC. | $130.30 | 2019-2023 | Tremfya |
| Pfizer INC. | $107.43 | 2019-2020 | |
| Lilly USA, LLC | $48.81 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $39.60 | 2019 | |
| Genzyme Corporation | $36.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.76 | 2023 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $25.00 | 2019 | |
| Biofrontera INC. | $23.89 | 2019 | |
| Dermira, INC. | $23.34 | 2019 | |
| Vyne Pharmaceuticals INC. | $22.17 | 2020 | |
| Ucb, INC. | $22.10 | 2019 | |
| Celgene Corporation | $21.51 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.43 | 2019 | |
| Epi Health, LLC | $15.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrienne Callahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.